Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAZIND)

Drug Name

Otlertuzumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 2	[1]
Peripheral T-cell lymphoma	2A90.C	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Leukocyte antigen CD37 (CD37)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI-836826	DMWH7Z5	Diffuse large B-cell lymphoma	2A81	Phase 2	[2]
IMGN529	DMNJ491	Non-hodgkin lymphoma	2B33.5	Phase 2	[3]
Naratuximab emtansine	DMSWUNX	Diffuse large B-cell lymphoma	2A81	Phase 2	[4]
TRU-016	DM9IQ4A	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[5]
GEN3009	DMD8RLY	B-cell non-hodgkin lymphoma	2B33.5	Phase 1/2	[6]
212Pb-labelled aCD37	DMLVADH	leukaemia	2A60-2B33	Preclinical	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opin Biol Ther. 2014 May;14(5):651-61.
3	The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014 Jul;28(7):1501-10.
4	Clinical pipeline report, company report or official report of Debiopharm.
5	TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs. 2009 Dec;10(12):1383-90.
6	Clinical pipeline report, company report or official report of AbbVie.
7	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.